The Evolving Scenario of ES-SCLC Management: From Biology to New Cancer Therapeutics.

Genes (Basel) · 2024 · PMC11203015 · PMID 38927637

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In the KEYNOTE-604 trial, pembrolizumab (an anti-PD-1) numerically improved PFS and OS; however, OS did not reach statistical significance [ 24 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.